Search
CEP-1347
go.drugbank.com/drugs/DB05403InvestigationalCEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons
Lisuride
go.drugbank.com/drugs/DB00589ApprovedIt may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists). … An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists).
Synonyms: N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylureaIncadronic acid
go.drugbank.com/drugs/DB06255Experimental[A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.
International brands: Yin FuPotassium triiodide
go.drugbank.com/drugs/DB14492InvestigationalCategories: Compounds used in a research, industrial, or household settingCarbendazim
go.drugbank.com/drugs/DB13009InvestigationalCarbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.
Categories: Compounds used in a research, industrial, or household settingImeglimin
go.drugbank.com/drugs/DB12509InvestigationalImeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.
Categories: Drugs Used in DiabetesCalcium cation
go.drugbank.com/drugs/DB14577InvestigationalSynonyms: calcium(2+) ionMixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 1000 CC SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 1000 CC SETSİZVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalVedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalIn preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases